MARVEL BIOSCIENCES CORP.

Communiqués Marvel Biosciences Corp.

Actions

MRVL

CA57384M1077

Temps Différé Toronto S.E. Autres places de cotation 15:30:00 02/07/2024			Varia. 5j.	Varia. 1 janv.
0,12 ^CAD	0,00%		+4,35%	+50,00%

18/06	Marvel Biosciences Corp. annonce ses résultats pour le troisième trimestre et les neuf mois clos le 30 avril 2024	CI
26/03	Marvel Biosciences Corp. annonce ses résultats pour le deuxième trimestre et le semestre clos le 31 janvier 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Marvel Biosciences Announces Private Placement Update	21/06	NE
Marvel Biosciences Announces Private Placement	17/05	NE
Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204	25/03	NE
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204	12/03	NE
Marvel Biosciences Announces Testing MB-204 on Autism by French University	20/02	NE
Marvel Biosciences Announces Closing of Non-Brokered Private Placement	19/01	NE
Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel	08/01	NE
Marvel Biosciences Invited to Test MB-204 on Autism by French University	16/11	NE
Marvel Successfully Completes the Dog and Rat GLP Toxicology Studies Required to enter Human Trials	21/04/23	AQ
Marvel Biosciences Initiates the Next Milestone Study for its Lead Asset MB-204 Targeting Alzheimer's and Depression	08/12/22	AQ
Marvel Biosciences Advances Closer to Human Trials after the Successful Completion of a Second Maximum Tolerated Dose Study, a Critical Milestone towards FDA Clinical Studies	26/10/22	AQ
Marvel Biosciences Announces Stock Option Grants	27/09/22	AQ
Marvel Biosciences Highlights Recent Research on Link between NASH and Alzheimer's disease	01/09/22	AQ
Marvel Biosciences Closes First Tranche of Private Placement	19/07/22	AQ
MARVEL BIOSCIENCES INITIATES FORMULATION DEVELOPMENT WITH CATALENT	07/04/22	AQ
Marvel Biosciences Provides Corporate Update as it Enters a Significant Value Creating Phase	09/02/22	AQ
Marvel Biosciences Corp. Announces Change of Chief Financial Officer	02/02/22	AQ
Marvel Biosciences Announces New Program to Develop Novel Orally Dosed Non-Hallucinogenic Neuroplastic Promoting Compounds	28/10/21	AQ
MARVEL BIOSCIENCES : TO PRESENT AT THE 22ND INTERNATIONAL CONFERENCE ON ALZHEIMER'S DRUG DISCOVERY	20/09/21	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Sécurisez et Augmentez la Performance de vos Investissements grâce à notre Équipe d'Experts à vos Côtés

Sécuriser mes Investissements

fermer